Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.

Molecular carcinogenesis - 1 Jun 2022

Naselsky Warren, Adhikary Gautam, Shrestha Suruchi, Chen Xi, Ezeka Geraldine, Xu Wen, Friedberg Joseph S, Eckert Richard L

Abstract excerpt

Transglutaminase 2 (TG2) is an important mesothelioma cancer cell survival protein. However, the mechanism whereby TG2 maintains mesothelioma cell survival is not well understood. We present studies showing that TG2 drives hepatocyte growth factor (HGF)-dependent MET receptor signaling to maintain the aggressive mesothelioma cancer phenotype. TG2 increases HGF and MET messenger RNA and protein levels to enhance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Movement
Share to Hepatocyte Growth Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mesothelioma

Share to Mesothelioma, Malignant

Share to Phenotype

Share to Protein Glutamine gamma Glutamyltransferase 2

Source

Open in PubMed Open full text

Identifiers

PMID: 35319795
DOI: 10.1002/mc.23399
PMCID: PMC10074999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.PMID 35319795Read ↗

Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.Semantic proximity Read ↗

The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.Semantic proximity Read ↗

Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53Semantic proximity Read ↗

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetSemantic proximity Read ↗

Tissue transglutaminase: a new target to reverse cancer drug resistanceSemantic proximity Read ↗

Loss of host tissue transglutaminase boosts antitumor T cell immunity by altering STAT1/STAT3 phosphorylation in ovarian cancerSemantic proximity Read ↗

The complex role of transglutaminase 2 in glioblastoma proliferationSemantic proximity Read ↗

The Role of Transglutaminase 2 in Cancer: An UpdateSemantic proximity Read ↗

The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour MicroenvironmentSemantic proximity Read ↗

Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.Semantic proximity Read ↗

Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.Semantic proximity Read ↗

Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.